However, due to the individual heterogeneity of bladder cancer, immunotherapy is not effective for some patients, and only a subset of patients can benefit from immune checkpoint inhibitors (ICIs) such as programmed cell death-1/programmed death-ligand 1 (PD-1/PD-L1) antibody immunotherapy [4]. This evidence concerns the gene PDCD1 and urinary bladder cancer.